Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Nov 2002Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials RICHARD J. SYLVESTER, ADRIAN P.M. van der MEIJDEN, and DONALD L. LAMM RICHARD J. SYLVESTERRICHARD J. SYLVESTER More articles by this author , ADRIAN P.M. van der MEIJDENADRIAN P.M. van der MEIJDEN More articles by this author , and DONALD L. LAMMDONALD L. LAMM Financial interest and/or other relationship with Schering, Aventis and Organon. More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64273-5AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of progression after transurethral resection to stage T2 disease or higher in patients with superficial (stage Ta, T1 or carcinoma in situ) bladder cancer. Materials and Methods: A meta-analysis was performed of the published results of randomized clinical trials comparing transurethral resection plus intravesical BCG to either resection alone or resection plus another treatment other than BCG. Results: We identified 24 trials with progression information on 4,863 patients. Based on a median followup of 2.5 years and a maximum of 15 years, 260 of 2,658 patients on BCG (9.8%) had progression compared to 304 of 2,205 patients in the control groups (13.8%), a reduction of 27% in the odds of progression on BCG (OR 0.73, p = 0.001). The percent of patients with progression was low (6.4% of 2,880 patients with papillary tumors and 13.9% of 403 patients with carcinoma in situ, reflecting the short followup and relatively low risk patients entered in many of the trials. The size of the treatment effect was similar in patients with papillary tumors and in those with carcinoma in situ. However, only patients receiving maintenance BCG benefited. There was no statistically significant difference in treatment effect for either overall survival or death due to bladder cancer. Conclusions: Intravesical BCG significantly reduces the risk of progression after transurethral resection in patients with superficial bladder cancer who receive maintenance treatment. Thus, it is the agent of choice for patients with intermediate and high risk papillary tumors and those with carcinoma in situ. References 1 : Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst1991; 83: 682. Google Scholar 2 : A combined analysis of European Organization for research and treatment of cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol1996; 156: 1934. Link, Google Scholar 3 : Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol1995; 153: 1444. Link, Google Scholar 4 : A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int2001; 88: 209. Google Scholar 5 : The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol1997; 158: 62. Link, Google Scholar 6 : A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?. J Urol1991; 146: 32. Link, Google Scholar 7 : A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol1987; 5: 441. Google Scholar 8 : Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol2000; 163: 1124. Link, Google Scholar 9 : Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol2001; 165: 1488. Link, Google Scholar 10 : Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol1996; 156: 56. Link, Google Scholar 11 : Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol1995; 154: 2050. Link, Google Scholar 12 : Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol1998; 160: 1668. Link, Google Scholar 13 : Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol1995; 1: 119. Google Scholar 14 : 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder cancer. J Urol1999; 161: 1124. Link, Google Scholar 15 : A multicenter and randomised prospective study comparing three intravesical therapies, two with bacillus Calmette-Guerin immunotherapy and one with mitomycin C chemotherapy in medium and low risk superficial bladder cancer. Eur Urol2001; 39: 32. abstract 119. Google Scholar 16 : Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer. Eur Urol1991; 20: 19. Google Scholar 17 : A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol1995; 153: 929. Link, Google Scholar 18 : Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacillus Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology1998; 52: 403. Google Scholar 19 : Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol1990; 143: 502. Google Scholar 20 : First results of a phase III study comparing BCG and epirubicin in TIS of the bladder: an EORTC GU Group study. Eur Urol2001; 39: 32. abstract 118. Google Scholar 21 : Intravesical 4′-epi-doxorubin (epirubicin) versus bacillus Calmette-Guerin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer1993; 72: 1749. Google Scholar 22 : Intravesical instillation of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk TA, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol2001; 166: 476. Abstract, Google Scholar 23 : Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol1982; 128: 27. Link, Google Scholar 24 : Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol1999; 36: 576. Google Scholar 25 : Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology1997; 50: 529. Google Scholar 26 : [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study.] Urologe A1994; 33: 133. Google Scholar 27 : [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study.] Urologe A1991; 30: 118. Google Scholar 28 : Prophylactic maltose tetrapalmitate and bacillus Calmette-Guerin immunotherapy of recurrent superficial bladder tumors: preliminary report. J Urol1988; 140: 498. Abstract, Google Scholar 29 : A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med1991; 325: 1205. Google Scholar 30 : Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol1995; 13: 1404. Google Scholar 31 : A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol1993; 149: 749. Link, Google Scholar 32 : Bacillus Calmette-Guerin (BCG)for transitional cell carcinoma of the bladder. In: Clinical Management of Bladder Cancer. Edited by . New York: Oxford University Press1999: 125. chapt. 5. Google Scholar 33 : Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol1986; 135: 272. Link, Google Scholar 34 : Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol1992; 147: 596. Link, Google Scholar From the European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium, Jeroen Bosch Hospital, ’ s-Hertogenbosch, The Netherlands, and the Mayo Clinic, Scottsdale, Arizona© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySharma V, Wymer K, Borah B, Saigal C, Litwin M, Packiam V, Thompson R, Tollefson M, Karnes R and Boorjian S (2020) Cost-Effectiveness of Maintenance bacillus Calmette-Guérin for Intermediate and High Risk Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 204, NO. 3, (442-449), Online publication date: 1-Sep-2020.Redrow G, Guo C, Brausi M, Coleman J, Fernandez M, Kassouf W, Keeley F, Margulis V, Raman J, Roupret M, Shariat S, Spiess P, Thalmann G and Matin S (2016) Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future DirectionJournal of Urology, VOL. 197, NO. 2, (287-295), Online publication date: 1-Feb-2017.Chang S (2016) Re: Prognostic Factors and Risk Groups in T1G3 Non-Muscle-Invasive Bladder Cancer Patients Initially Treated with bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 PatientsJournal of Urology, VOL. 195, NO. 5, (1382-1382), Online publication date: 1-May-2016.Geijsen E, de Reijke T, Koning C, Zum Vörde Sive Vörding P, de la Rosette J, Rasch C, van Os R and Crezee J (2015) Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot StudyJournal of Urology, VOL. 194, NO. 5, (1202-1208), Online publication date: 1-Nov-2015.Gaya J, López-Martínez J, Karni-Schmidt O, Bonal D, Algaba F, Palou J, Villavicencio H, Benson M, Cordon-Cardo C and Castillo-Martin M (2014) ΔNp63 Expression is a Protective Factor of Progression in Clinical High Grade T1 Bladder CancerJournal of Urology, VOL. 193, NO. 4, (1144-1150), Online publication date: 1-Apr-2015.Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J and Kamat A (2014) Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-GuérinJournal of Urology, VOL. 193, NO. 4, (1135-1143), Online publication date: 1-Apr-2015.Lamm D, Persad R, Brausi M, Buckley R, Witjes J, Palou J, Böhle A, Kamat A, Colombel M and Soloway M (2013) Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard DefinitionJournal of Urology, VOL. 191, NO. 1, (20-27), Online publication date: 1-Jan-2014.Dinney C, Fisher M, Navai N, O'Donnell M, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman H, Kamat A, Gonzales M, Kincaid M, Ainslie N, Maneval D, Wszolek M and Benedict W (2013) Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 190, NO. 3, (850-856), Online publication date: 1-Sep-2013.Sengiku A, Ito M, Miyazaki Y, Sawazaki H, Takahashi T and Ogura K (2013) A Prospective Comparative Study of Intravesical Bacillus Calmette-Guérin Therapy with the Tokyo or Connaught Strain for Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 190, NO. 1, (50-54), Online publication date: 1-Jul-2013.Johnson M, Nepple K, Peck V, Trinkaus K, Klim A, Sandhu G and Kibel A (2012) Randomized Controlled Trial of Oxybutynin Extended Release Versus Placebo for Urinary Symptoms During Intravesical Bacillus Calmette-Guérin TreatmentJournal of Urology, VOL. 189, NO. 4, (1268-1274), Online publication date: 1-Apr-2013.Barlow L, McKiernan J and Benson M (2012) Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin TherapyJournal of Urology, VOL. 189, NO. 3, (834-839), Online publication date: 1-Mar-2013.Secanella-Fandos S, Luquin M and Julián E (2012) Connaught and Russian Strains Showed the Highest Direct Antitumor Effects of Different Bacillus Calmette-Guérin SubstrainsJournal of Urology, VOL. 189, NO. 2, (711-718), Online publication date: 1-Feb-2013.van Rhijn B, van der Kwast T, Liu L, Fleshner N, Bostrom P, Vis A, Alkhateeb S, Bangma C, Jewett M, Zwarthoff E, Zlotta A and Bapat B (2011) The FGFR3 Mutation is Related to Favorable pT1 Bladder CancerJournal of Urology, VOL. 187, NO. 1, (310-314), Online publication date: 1-Jan-2012.Brausi M, Witjes J, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A (2011) A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer GroupJournal of Urology, VOL. 186, NO. 6, (2158-2167), Online publication date: 1-Dec-2011.Rosevear H, Lightfoot A, Birusingh K, Maymí J, Nepple K and O'Donnell M (2011) Factors Affecting Response to Bacillus Calmette-Guérin Plus Interferon for Urothelial Carcinoma in SituJournal of Urology, VOL. 186, NO. 3, (817-823), Online publication date: 1-Sep-2011.Nepple K, Lightfoot A, Rosevear H, O'Donnell M and Lamm D (2010) Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 184, NO. 5, (1915-1919), Online publication date: 1-Nov-2010.Guevara A, Salomon L, Allory Y, Ploussard G, de la Taille A, Paul A, Yiou R, Hoznek A, Dahan M, Abbou C and Vordos D (2010) The Role of Tumor-Free Status in Repeat Resection Before Intravesical Bacillus Calmette-Guerin for High Grade Ta, T1 and CIS Bladder CancerJournal of Urology, VOL. 183, NO. 6, (2161-2164), Online publication date: 1-Jun-2010.Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho J, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M and Martinez-Piñeiro J (2009) Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring ModelJournal of Urology, VOL. 182, NO. 5, (2195-2203), Online publication date: 1-Nov-2009.Serretta V, Ruggirello A, Dispensa N, Allegro R, Aragona F and Melloni D (2008) Multiplicity and History Have a Detrimental Effect on Survival of Patients With T1G3 Bladder Tumors Selected for Conservative TreatmentJournal of Urology, VOL. 180, NO. 3, (886-891), Online publication date: 1-Sep-2008.Lamm D (2008) Re: A Randomized Trial of Radical Radiotherapy for the Management of pT1G3 NXM0 Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 179, NO. 4, (1639-1641), Online publication date: 1-Apr-2008.Lamm D (2007) Re: Patterns of Recurrence and Outcomes Following Induction Bacillus Calmette-Guerin for High Risk Ta, T1 Bladder CancerJournal of Urology, VOL. 179, NO. 2, (788-788), Online publication date: 1-Feb-2008.Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E, Wolf J and Schellhammer P (2018) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, VOL. 178, NO. 6, (2314-2330), Online publication date: 1-Dec-2007.Di̇vri̇k R, Şahi̇n A, Altok M, Ünlü N and Zorlu F (2007) The Frequency of Hydronephrosis at Initial Diagnosis and its Effect on Recurrence and Progression in Patients With Superficial Bladder CancerJournal of Urology, VOL. 178, NO. 3, (802-806), Online publication date: 1-Sep-2007.Harland S, Kynaston H, Grigor K, Wallace D, Beacock C, Kockelbergh R, Clawson S, Barlow T, Parmar M and Griffiths G (2007) A Randomized Trial of Radical Radiotherapy for the Management of pT1G3 NXM0 Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 178, NO. 3, (807-813), Online publication date: 1-Sep-2007.Lerner S, Tangen C, Sucharew H, Wood D and Crawford E (2018) Patterns of Recurrence and Outcomes Following Induction Bacillus Calmette-Guerin for High Risk Ta, T1 Bladder CancerJournal of Urology, VOL. 177, NO. 5, (1727-1731), Online publication date: 1-May-2007.van der Heijden A, Moonen P, Cornel E, Vergunst H, de Reijke T, van Boven E, Barten E, Puri R, van Kalken C and Witjes J (2018) Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker ResponseJournal of Urology, VOL. 176, NO. 4, (1349-1353), Online publication date: 1-Oct-2006.Yossepowitch O, Eggener S, Bochner B, Donat S, Herr H and Dalbagni G (2018) Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Instillations in Steroid Treated and Immunocompromised PatientsJournal of Urology, VOL. 176, NO. 2, (482-485), Online publication date: 1-Aug-2006.Lamm D (2018) Editorial CommentJournal of Urology, VOL. 175, NO. 5, (1639-1640), Online publication date: 1-May-2006.Koya M, Simon M and Soloway M (2018) Complications of Intravesical Therapy for Urothelial Cancer of the BladderJournal of Urology, VOL. 175, NO. 6, (2004-2010), Online publication date: 1-Jun-2006.MARTÍNEZ-PIÑEIRO J, MARTÍNEZ-PIÑEIRO L, SOLSONA E, RODRÍGUEZ R, FERNÁNDEZ GÓMEZ J, MARTÍN M, MOLINA J, COLLADO A, FLORES N, ISORNA S, PERTUSA C, RABADÁN M, ASTOBIETA A, CAMACHO J, ARRIBAS S and MADERO R (2018) HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIALJournal of Urology, VOL. 174, NO. 4 Part 1, (1242-1247), Online publication date: 1-Oct-2005.MULLERAD M, BOCHNER B, ADUSUMILLI P, BHARGAVA A, KIKUCHI E, HUI-NI C, KATTAN M, CHOU T and FONG Y (2018) HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMAJournal of Urology, VOL. 174, NO. 2, (741-746), Online publication date: 1-Aug-2005.SYLVESTER R, van der MEIJDEN A, WITJES J and KURTH K (2018) BACILLUS CALMETTE-GUERIN VERSUS CHEMOTHERAPY FOR THE INTRAVESICAL TREATMENT OF PATIENTS WITH CARCINOMA IN SITU OF THE BLADDER: A META-ANALYSIS OF THE PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology, VOL. 174, NO. 1, (86-91), Online publication date: 1-Jul-2005.ZHANG G, CHEN F, XU Y, CAO Y, CRIST S, McKERROW A, IWAMOTO Y and SEE W (2018) AUTOCRINE OVER EXPRESSION OF FIBRONECTIN BY HUMAN TRANSITIONAL CARCINOMA CELLS IMPAIRS BACILLUS CALMETTE-GUERIN ADHERENCE AND SIGNALINGJournal of Urology, VOL. 172, NO. 4 Part 1, (1496-1500), Online publication date: 1-Oct-2004.SCHMIDBAUER J, WITJES F, SCHMELLER N, DONAT R, SUSANI M and MARBERGER M (2018) Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence CystoscopyJournal of Urology, VOL. 171, NO. 1, (135-138), Online publication date: 1-Jan-2004.BÖHLE A and BRANDAU S (2018) Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder CancerJournal of Urology, VOL. 170, NO. 3, (964-969), Online publication date: 1-Sep-2003.Grossman H (2018) Editorial: Immunotherapy for Bladder Cancer. Is the Black Box Becoming Grayer?Journal of Urology, VOL. 169, NO. 5, (1709-1709), Online publication date: 1-May-2003. Volume 168Issue 5November 2002Page: 1964-1970 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsmeta-analysisdisease progressionbladder neoplasmsMetricsAuthor Information RICHARD J. SYLVESTER More articles by this author ADRIAN P.M. van der MEIJDEN More articles by this author DONALD L. LAMM Financial interest and/or other relationship with Schering, Aventis and Organon. More articles by this author Expand All Advertisement PDF downloadLoading ...